A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
Zymeworks Inc.
ZYME
$1.7B
Mkt Cap
$22.86
-1.12%
Zymeworks Inc. (ZYME) has a 5-year average return on invested capital (ROIC) of -36.4%. This is below average and may indicate limited pricing power.
Zymeworks Inc. (ZYME) has a market capitalization of $1.7B. It is classified as a small-cap stock.
Zymeworks Inc. (ZYME) does not currently pay a regular dividend. However, the company returns capital to shareholders through share buybacks, with a buyback yield of 2.50%.
Zymeworks Inc. (ZYME) operates in the Pharmaceutical Preparations industry, within the Healthcare sector.
Zymeworks Inc. (ZYME) reported annual revenue of $106 million in its most recent fiscal year, based on SEC EDGAR filings.
Zymeworks Inc. (ZYME) has a net profit margin of -76.6%. The company is currently unprofitable.
Zymeworks Inc. (ZYME) generated $-35 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Zymeworks is a global biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics to improve the standard of care for difficult-to-treat conditions, including cancer, inflammation, and autoimmune disease. We believe our asset and royalty aggregation strategy differentiates us from other biotechnology companies because it provides us with an opportunity to optimize future milestone and royalty cash flows and selectively invest in high-quality assets while retaining the flexibility to return capital to stockholders. Our Strategy Our strategy is focused on compounding long-term stockholder value through a combination of royalty growth, strategic acquisitions, and internal innovation, supported by disciplined capital allocation and a strengthened financial foundation through expected milestone payments and royalties from existing commercial partners.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | % of Total |
|---|---|---|---|---|---|---|
Glaxo Smith Kline Intellectual Property Development Ltd | — | $6M | $6M | $6M | $867M | 74% |
Daiichi Sankyo, Co., Ltd. (“Daiichi Sankyo”): | — | — | $5M | — | $170M | 14% |
Janssen Biotech, Inc. | — | — | — | $50M | $50M | 4% |
Johnson & Johnson Innovative Medicine (previously known as Janssen Biotech, Inc.) (“J&J”): | — | — | — | — | $25M | 2% |
BeOne Medicines Ltd. (previously known as BeiGene, Ltd.) (“BeOne”): | $8M | — | $144M | $8M | $20M | 2% |
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 81M | 106M | 76M | 76M | 412M | - |
| Net Income | -103M | -81M | -123M | -119M | 124M | -212M |
| EPS | $-1.39 | $-1.08 | $-1.62 | $-1.72 | $1.90 | $-4.61 |
| Free Cash Flow | -77M | -35M | -112M | -121M | 136M | -205M |
| ROIC | -18.8% | -26.7% | -30.4% | -24.7% | 377.0% | -64.0% |
| Gross Margin | - | - | 88.7% | - | - | - |
| Debt/Equity | 0.00 | 0.07 | 0.06 | 0.06 | 0.06 | 0.14 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -114M | -93M | -137M | -138M | 131M | -216M |
| Operating Margin | -140.4% | -87.3% | -179.7% | -181.6% | 31.6% | - |
| ROE | -62.8% | -26.7% | -30.5% | -24.8% | 33.5% | -64.3% |
| Shares Outstanding | 73M | 75M | 76M | 69M | 65M | 46M |
| Metric | |||||||
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | N/A | N/A | 412M | 76M | 76M | 106M | 81M |
| Gross Margin | N/A | N/A | N/A | N/A | 88.7% | N/A | N/A |
| R&D | 171M | 200M | 209M | 144M | 135M | 137M | 136M |
| SG&A | 55M | 43M | 73M | 70M | 62M | 62M | 60M |
| EBIT | -187M | -216M | 131M | -138M | -137M | -93M | -114M |
| Op. Margin | N/A | N/A | 31.6% | -181.6% | -179.7% | -87.3% | -140.4% |
| Net Income | -181M | -212M | 124M | -119M | -123M | -81M | -103M |
| Net Margin | N/A | N/A | 30.1% | -156.1% | -160.8% | -76.6% | -126.3% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Returns on Capital | |||||||
| ROIC | N/A | -64.0% | N/M | -24.7% | -30.4% | -26.7% | -18.8% |
| ROE | N/A | -64.3% | 33.5% | -24.8% | -30.5% | -26.7% | -62.8% |
| ROA | -4340.2% | -107.7% | 24.0% | -19.3% | -23.5% | -20.0% | -21.5% |
| Cash Flow | |||||||
| Op. Cash Flow | -151M | -192M | 144M | -118M | -110M | -33M | -75M |
| Free Cash Flow | -156M | -205M | 136M | -121M | -112M | -35M | -77M |
| Owner Earnings | -188M | -210M | 127M | -147M | -137M | -69M | -125M |
| CapEx | 4.3M | 12M | 8.1M | 2.5M | 2.0M | 1.5M | 1.7M |
| Maint. CapEx | 7.5M | 6.5M | 13M | 21M | 8.7M | 7.7M | 21M |
| Growth CapEx | 0 | 5.9M | 0 | 0 | 0 | 0 | 0 |
| D&A | 7.5M | 6.5M | 13M | 21M | 8.7M | 7.7M | 21M |
| CapEx/OCF | N/A | N/A | 5.7% | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 30M | 42M | 42M |
| Buyback Yield | N/A | N/A | N/A | N/A | 2.7% | 2.1% | 2.5% |
| Stock-Based Comp | 29M | 11M | 4.0M | 8.1M | 18M | 28M | 29M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||||
| Net Debt | N/A | -218M | -461M | -346M | -330M | -219M | -244M |
| Cash & Equiv. | 242M | 202M | 401M | 158M | 66M | 41M | 244M |
| Long-Term Debt | N/A | 2.7M | 3.1M | 1.7M | 923K | 278K | 278K |
| Debt/Equity | N/A | 0.14 | 0.06 | 0.06 | 0.06 | 0.07 | 0.00 |
| Interest Coverage | N/A | N/A | 36.3 | -7.0 | -6.9 | -6.9 | -6.9 |
| Equity | N/A | 249M | 493M | 465M | 339M | 269M | 164M |
| Total Assets | 4.2M | 389M | 649M | 581M | 463M | 347M | 478M |
| Total Liabilities | N/A | 140M | 156M | 116M | 124M | 78M | 315M |
| Intangibles | N/A | 3.8M | 8.8M | 7.7M | 4.6M | 1.4M | 1.2M |
| Retained Earnings | N/A | -683M | -559M | -677M | -830M | -953M | -1.1B |
| Working Capital | N/A | 216M | 449M | 357M | 212M | 206M | 350M |
| Current Assets | N/A | 288M | 545M | 413M | 300M | 249M | 386M |
| Current Liabilities | N/A | 72M | 96M | 56M | 88M | 42M | 36M |
| Per Share Data | |||||||
| EPS | -3.58 | -4.61 | 1.90 | -1.72 | -1.62 | -1.08 | -1.39 |
| Owner EPS | -3.73 | -4.56 | 1.94 | -2.13 | -1.80 | -0.92 | -1.71 |
| Book Value | N/A | 5.42 | 7.53 | 6.74 | 4.47 | 3.57 | 2.24 |
| Cash Flow/Share | -3.00 | -4.19 | 2.20 | -1.71 | -1.45 | -0.44 | -1.12 |
| Dividends/Share | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 50.4M | 46.0M | 65.4M | 69.0M | 75.7M | 75.1M | 73.1M |
| Valuation | |||||||
| P/E Ratio | N/A | N/A | 3.9 | N/A | N/A | N/A | -16.5 |
| P/FCF | N/A | N/A | 3.6 | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 2.9 | 1.0 | 1.6 | 3.2 | 7.5 | 10.2 |
| Price/Sales | N/A | N/A | 1.1 | 7.5 | 11.1 | 10.9 | 20.6 |
| FCF Yield | -6.2% | -28.3% | 27.7% | -16.4% | -10.2% | -1.7% | -4.6% |
| Market Cap | 2.5B | 724M | 490M | 738M | 1.1B | 2.0B | 1.7B |
| Avg. Price | 39.58 | 31.95 | 7.13 | 8.24 | 11.20 | 15.33 | 22.86 |
| Year-End Price | 49.78 | 15.76 | 7.49 | 10.70 | 14.50 | 26.87 | 22.86 |
Zymeworks Inc. passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 88.7%. Total shareholder yield (buybacks) is 2.5%. At current prices, the estimated annualized return to fair value is +1.7%.
Zymeworks Inc. (ZYME) has a debt-to-equity ratio of 0.07. This indicates a conservatively financed balance sheet.
Zymeworks Inc. (ZYME) reported earnings per share (EPS) of $-1.08 in its most recent fiscal year.
Zymeworks Inc. (ZYME) has a return on equity (ROE) of -26.7%. A negative ROE may indicate losses or negative equity.
Zymeworks Inc. (ZYME) has a 5-year average gross margin of 88.7%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 6 years of financial data for Zymeworks Inc. (ZYME), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Zymeworks Inc. (ZYME) has a book value per share of $3.57, based on its most recent annual SEC filing.